Cara Therapeutics (CARA) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Cara Therapeutics faces a significant business risk after receiving notification from Nasdaq of non-compliance with its minimum bid price rule. If the company’s stock price does not recover to meet Nasdaq’s standards by July 30, 2024, the potential delisting could substantially diminish market liquidity and the stock’s market value. A delisting could deter investor interest, hinder Cara Therapeutics’ ability to raise funds through equity financing, and possibly tarnish the company’s reputation and operational prospects. This development raises concerns about the firm’s future financial stability and investor confidence.
The average CARA stock price target is $6.88, implying 555.24% upside potential.
To learn more about Cara Therapeutics’ risk factors, click here.
